

# ActiveCare®

## VS

# Enoxaparin

**ActiveCare® + 100mg ASA compared with enoxaparin for the prevention of venous thromboembolism after total knee and total hip arthroplasties**

Yael Gelfer  
Hovav Tavor  
Amir Oron  
Amir Peer  
Nachum Halperin  
Dror Robinson

---

**The Journal of Arthroplasty Vol. 21 (2), February 2006**

---

**MCS**  
Medical Compression  
Systems Inc.

# DVT Prevention in Joint Arthroplasties: Continuous Enhanced Circulation Therapy (ActiveCare<sup>®</sup>) vs LMWH.



# OBJECTIVE

To compare the efficacy and safety of the **ActiveCare** versus enoxaparin (40 mg) in preventing venous thromboembolism (VTE) in patients undergoing elective total knee arthroplasty (TKA) or total hip arthroplasty (THA).

# INCLUSION CRITERIA


Adult patients undergoing elective TKA or THA surgery.

# DESIGN

A prospective, randomized, treatment controlled study.

# ENDPOINTS

**Primary Efficacy** - VTE defined as deep vein thrombosis as detected by bilateral venography (up to day 8 postoperative), or documented symptomatic deep vein thrombosis and pulmonary embolism (up to 90 days postoperative).



■ **ActiveCare**® is the brand name of a medical device classified as Continued Enhanced Circulation Therapy (**C.E.C.T.**).

# RESULTS

**Summary** - One hundred and twenty-one patients were available for per-protocol analysis: Sixty-one patients were randomized to the **ActiveCare** group and sixty were randomized to the enoxaparin group.


**Efficacy** - The **ActiveCare** group was significantly more effective than enoxaparin in reducing VTE.

**Safety** - Safety profiles were similar in both groups.

## DVT OUTCOME

	ActiveCare®	ENOXAPARIN	P VALUE
TOTAL DVT	6.6% (4/61)	28.3% (17/60)	P=0.002
PROXIMAL DVT	1.6% (1/61)	10.0% (6/60)	P=0.049

ODDS RATIO: 6.5 (95% C.I: 1.95-21.4, P=0.002)



## EVIDENCE-BASED CONCLUSION

In patients undergoing elective TKA & THA, the **ActiveCare** group was at least two times more effective than enoxaparin in preventing VTE.

# TECHNICAL SPECIFICATIONS

<b>INDICATION</b>	DVT prophylaxis, reduction of post-operative pain and swelling, reduction of wound healing time
<b>SIZE</b>	5.3 x 5.3 x 2.4 in (135 x 135 x 60 mm)
<b>WEIGHT</b>	730 g / 1.6 lb (including battery)
<b>POWER INPUT</b>	9.7 VDC
<b>BATTERY*</b>	7.2 V (rechargeable NiMH)
Battery life	5h (after full recharge)
Recharge time	4-5 h
<b>CHARGER</b>	Built-in
<b>MAINS SUPPLY</b>	100-240V, 50/60 Hz
<b>INFLATION MODE</b>	Sequential compression
<b>PRESSURE (preset)</b>	
Calf	50 mmHg ( ± 10%)
Foot	130 mmHg ( ± 10%)
Thigh	50 mmHg ( ± 10%)
<b>COMPRESSION</b>	
<b>DURATION</b>	
Calf	Up to 10 sec
Foot	Up to 6 sec (depending on model)
Thigh	Up to 15 sec (depending on model)
<b>PULSE FREQUENCY</b>	
Calf	1 per minute
Foot	2 per minute
Thigh	1 per minute

\*Battery life and recharge may vary depending on usage.

**WARNING:** Use only the battery pack provided by MCS.

Use of any alternative power source could cause irreparable damage to the system!

All MCS products are LATEX FREE  
FDA CLASS II Prescription device

